Recommendations by the Civil Society Forum on Drugs to the Horizontal Drugs Group on the 2019 High Level Ministerial Meeting

January 2018

In November 2017, the Civil Society Forum on Drugs (CSFD) produced a position statement on the 2019 High Level Ministerial Segment on drugs.¹ This new contribution aims to complement our position statement and to respond to the various questions raised during the joint CSFD/HDG meeting held on 29th November 2017.

Evaluating the goals and targets included in the 2009 Political Declaration

2019 constitutes a critical opportunity for a long-overdue evaluation of progress made since the adoption of the 2009 Political Declaration. This review is particularly urgent as the UNODC is in the process of updating the Annual Report Questionnaire (ARQ) to reflect the new priority areas included within the UNGASS Outcome Document.

The United Nations have a long tradition of evaluating progress made and impact – and the UNODC is not an exception. Indeed, the UNODC Independent Evaluation Unit (IEU) is mandated to evaluate the 'implementation, performance and impact' of UNODC's programmes.² The UNODC could task the IEU to contribute to an evaluation of progress made in global drug control since 2009³ via a cross-UN working group under the leadership of the UNODC Executive Director. The objective being to measure what has and has not been achieved within the goals set forth in the 2009 Political Declaration and Plan of Action, while also taking into consideration the additional aspects covered in the UNGASS Outcome Document, especially in the areas of human rights, health and development.

To ensure a transparent and participatory process, the cross-UN working group should call for inputs from member states, UN agencies and civil society – using a model similar to the pre-UNGASS call for contributions. These submissions should be considered seriously and, to the extent possible, be incorporated in the review. The final report should form the basis of discussions on the review of the 2009 Political Declaration at the 2019 High Level Ministerial Segment.

Establishing new metrics and indicators for global drug control

It is now widely acknowledged that many of the goals and targets set out in the 2009 Political Declaration and Plan of Action on drug control were unrealistic and often harmful. As the 2009 goals and targets will expire in 2019, the High Level Ministerial Segment presents a key opportunity to consider new indicators to evaluate progress in global drug control for the next decade. This issue is becoming all the more relevant with the ARQ review by UNODC. The identification of new indicators should be led by the following key principles:

• Consider both *process* indicators (i.e. activities to achieve the stated objectives) and *outcome* indicators (i.e. impacts of these activities) – in 2009, the outcome indicators were mostly focused on the unrealistic objective of reducing the scale of the illicit market, with little attention given to the diverse and complex consequences of drug markets and drug policies on health, human rights,

¹ Available here: <u>https://www.dropbox.com/s/fv5iutzaeqb2pm2/2017-</u>

^{11%20}CSFD%20recommendations%20on%202019%20review_FINAL.pdf?dl=0

² For more information, see: <u>http://www.unodc.org/unodc/en/evaluation/the-independent-evaluation-unit.html</u>

³ United Nations Office on Drugs and Crime (2015), UNODC evaluation policy: Independent Evaluation Unit,

http://www.unodc.org/documents/evaluation/IEUwebsite/Evaluation_Policy/UNODC_Evaluation_Policy.pdf

development and security. More relevant indicators could be identified to ensure that these aspects are measured accordingly.

- Incorporate the *new aspects* of global drug control enshrined in the UNGASS Outcome Document, in particular in the areas of human rights, availability of controlled medicines, improved access to health services and better impacts on health, and the implementation of development programmes in areas affected by supply-side activities to reduce the risk factors of engagement in illicit economies.
- Embed these new metrics and indicators in the broader framework of the *Sustainable Development Goals* (SDGs), especially SDG 1 (No poverty), 3 (Good health and well-being), 5 (Gender equality), 8 (Decent work and economic growth) and 16 (Peace, justice and strong institutions).

Key issues to consider when reviewing the ARQ

The UNGASS Outcome Document directly mandates the UNODC to collect data on a variety of issues, which should be incorporated in the revised ARQ. These include:

- Collection and analysis of... age- and gender-related data (preamble)
- Reliable and comparable data on drug use and epidemiology, including on social, economic and other risks factors encouraging drug use (para 1.h)
- Prevention and countering of drug-related crime and drug supply reduction measures (para 3.c)
- Links between drug trafficking, corruption and other forms of organised crime (para 3.k)
- Money-laundering and illicit financial flows (para 3.r)
- The promotion of human rights and the health, safety and welfare of all individuals, communities and society (para 4.h)
- Trends in the composition, production, prevalence and distribution of NPS, as well as patterns of use and adverse consequences (para 5.d)
- Drug-related criminal activities using the Internet (para 5.p)
- Factors contributing to illicit crop cultivation... with a view to increasing the effectiveness of these programmes, including through the use of relevant human development indicators (para 7.g).

The UNGASS Outcome Document also includes a number of new issues on which member states should consider reporting on a voluntary basis – in particular on ensuring access to controlled medicines. To do so, the ARQ could consider expanding its 'Additional Comments' sections and/or indicating optional sections for member states to complete.

Gaps in data collection on these optional topics will require the UNODC to turn to additional data sources – including information being collected by other UN agencies such as WHO,⁴ UNAIDS,⁵ UNICEF,⁶ the INCB,⁷ the World Bank,⁸ the OHCHR,⁹ UNICRI,¹⁰ the Committee on the Prevention of Discriminations Against Women,¹¹ the United Development Programme via the Human Development Index,¹² and on progress towards the Sustainable Development Goals.¹³ For particularly controversial issues (e.g. reporting on human rights

⁴ <u>http://www.who.int/whosis/en/</u>

www.unaids.org/en/dataanalysis

www.unicef.org/statistics

http://www.incb.org/incb/en/publications/annual-reports/annual-report.html

⁸ <u>http://data.worldbank.org</u>

⁹ http://www.ohchr.org/EN/PublicationsResources/Pages/databases.aspx

¹⁰ http://www.unicri.it

http://www.un.org/womenwatch/daw/cedaw/reports.htm

¹² www.undp.org and http://hdr.undp.org/en/content/human-development-index-hdi

¹³ <u>https://sustainabledevelopment.un.org/sdgs</u>, and in particular the voluntary reporting provided to member states via the High Level Political Forums: https://sustainabledevelopment.un.org/hlpf

obligations), this may also require the consideration of civil society sources. Such an approach would help reduce the additional burden on member states for data collection, while promoting more system-wide coherence and cooperation across the UN system.

We present below a proposal for a more focused ARQ framework, better able to capture the impact of global drug policies, and aligned both with the UNGASS Outcome Document and the SDGs. The Matrix that follows proposes a new set of indicators to populate this framework – with cross-references to the UNGASS Outcome Document, the SDGs and the EU Action Plan on Drugs 2017-2020.

For each of these targets and indicators, the revised ARQ should clearly specify which areas are mandatory, which are voluntary, and which could benefit from additional data sources, to support member states in filling in the questionnaire and improve the response rate.

A revised framework for the ARQ

PART I: Legislative and institutional framework

Short section in which member states are able to report back on any new drug legislation, regulation or administrative measure adopted or revised during the reporting period.

PART II: Demand reduction and related measures, including prevention and treatment, as well as other health-related issues

Target 1: Achieve a measurable reduction in drug use, problematic drug use and drug dependence

Target 2: Achieve a measurable reduction in HIV/AIDS, viral hepatitis and other blood-borne infectious diseases among people who use drugs

PART III: Ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes, while preventing their diversion

Target 3: Achieve a measurable improvement in availability of, and access to, controlled substances for medical and scientific purposes

PART IV: Supply reduction and related measures; effective law enforcement; responses to drug-related crime; and countering money-laundering and promoting judicial cooperation

Target 4: Achieve a measurable reduction in drug-related crime

Target 5: Achieve a measurable reduction in organised crime, including money-laundering, corruption and other criminal activities

PART V: Cross-cutting issues: Drugs and human rights, youth, children, women and communities

Target 6: Apply a human rights-based approach in the design and implementation of drug control policies and programmes aiming to contribute to the protection of human rights of youth, women, children, vulnerable members of society, and communities

Target 7: Achieve more proportionate policies and responses for drug offences; and ensure the protection of legal guarantees and safeguards pertaining to criminal justice proceedings

PART VI: Cross-cutting issues: Evolving reality, trends and existing circumstances, emerging and persistent challenges and threats, including new psychoactive substances

Target 8: Achieve a measurable reduction in the threat and harms posed by NPS, ATS, including methamphetamine, and the diversion of precursors and pre-precursors, including adverse health consequences

Target 9: Improve research, data collection, analysis, technical assistance and capacity building to tackle the use of the internet, and monitor evolving realities, trends and emerging and persistent challenges and threats

PART VII: Strengthening international cooperation based on the principle of common and shared responsibility

Target 10: Increase technical assistance and cooperation through relevant UN agencies and international and regional organizations to effectively address the health, socioeconomic, human rights, justice and law enforcement aspects of the world drug problem

Target 11: Improve international cooperation, exchange of information and lessons learned between member states, and with all relevant United Nations entities, in tackling the world drug problem

PART VIII: Alternative development; regional, interregional and international cooperation on developmentoriented balanced drug control policy; addressing socioeconomic issues

Target 12: Measurably improve the socioeconomic condition of communities in areas affected by illicit drug cultivation, manufacture, production and trafficking

Target 13: Increased technical and financial cooperation for the implementation of development-oriented drug policies and viable economic alternatives

Process/outcome indicator	Relevant section in the UNGASS outcome Document	Para. in UNGASS Outcome Document	Ref. in EU Action Plan on Drugs	Ref. in the SDGs	Additional data sources
PART II: Demand r	eduction and related measures, including prevention and treatment				
Target 1: Achieve a	a measurable reduction in drug use, problematic drug use and drug o	lependence			
Process indicator	Adoption of minimum quality standards for drug prevention, modelled on those developed by UNODC ¹⁴	Para 1.h	Action 10	Target 3.5	EMCDDA
	Adoption of measures to address the social, economic and other risk factors of drug use and dependence	Para 1.h	Action 1	Target 1.1	
	Legislation, regulation or administrative measure adopted or	Para 1.i	Action 10.d	Target 3.5	
	reviewed to promote voluntary access to evidence-based treatment	Para 1.j			
	Training of healthcare staff on evidence-based drug dependence treatment	Para 1.p	Action 6.a		
Outcome indicator	Delay in the age of first use of drugs among youth	Para 1.a	Action 2	Indicator 1.1.1	
	Number of people who use drugs having access to healthcare information and services	Para 1.h	Action 1	Indicator 3.8.1	UNAIDS WHO
	Number of people arrested by the police for drug use or simple possession ¹⁵	Para 1.h	Action 22		CCPCJ
	Number of people processed through the criminal justice system for drug use or simple possession ¹⁶	Para 1.h	Action 22		ССРСЈ
	Number of people incarcerated for drug use or simple possession ¹⁷	Para 1.h	Action 22		CCPCJ
	Number of people dependent on drugs accessing voluntary drug treatment, number of those who completed their treatment programme, and retention rate for drug treatment programmes (disaggregated by age, gender)	Para 1.j	Action 10	Indicator 3.5.1	WHO
	Number of people accessing drug dependence treatment in prison (disaggregated by age, gender)	Para 4.m	Action 9	Indicator 3.5.1	

¹⁴ ARQ Part II Question 9(f)(i) requests governments to report back on 'written and approved standards' for treatment, but does not request similar information on prevention (also in line with paras 1.i, 1.p and 4c of the UNGASS Outcome Document. A similar request should me made with regards to prevention, especially to track progress made in the implementation of UNODC's own International standards on drug use prevention: <u>https://www.unodc.org/documents/prevention/UNODC_2013_2015_international_standards_on_drug_use_prevention_E.pdf</u> ¹⁵ To complement data already being collected in ARQ Part IV, questions 25-26

¹⁷ Ibid

¹⁶ Ibid

	Reported cases of acts of cruel, inhuman or degrading treatment or punishment in rehabilitation facilities (disaggregated by age,	Para 4.c	Action 51.h	Indicator 11.7.2	WHO OHCHR
	gender) Reported cases of discrimination in accessing drug dependence treatment (disaggregated by age, gender)	Para 1.j	Target 10.3 Target 16.a Indicator 10.3.1	Target 16.B Indicator 10.3.1 Indicator 16.B.1	WHO
Target 2: Achieve	a measurable reduction in HIV/AIDS, viral hepatitis and other blood-	borne infectious dise			
Process indicator	Drug legislation, regulations or administrative measures adopted or revised to remove barriers in accessing healthcare services for people who use drugs (including prevention, treatment and care of blood-borne infections and overdose prevention)	Para 1.o	Action 8.c	Target 3.3	UNAIDS
	Availability & coverage of needle and syringe exchange programmes among people who use drugs, disaggregated by age and gender	Para 1.o	Action 8.a		WHO UNAIDS
	Availability & coverage of substitution therapy among people dependent on opioids, disaggregated by age and gender	Para 1.k Para 1.o	Action 8.a	Target 3.5	WHO UNAIDS
	Coverage of treatment for viral hepatitis among people who use drugs, disaggregated by age and gender	Para 1.o	Action 8.a		WHO UNAIDS
	Availability of naloxone (among peers, in hospitals, in healthcare facilities, etc.) ¹⁹	Para 1.m	Action 8.b		WHO UNAIDS
	Availability of other measures aimed at reducing the risks and harms related to drug use, disaggregated by age and gender	Para 1.o	Action 8.a and 8.b		WHO UNAIDS
Dutcome indicator	HIV incidence, treatment rate, and mortality among people who use drugs, disaggregated by age and gender ²⁰	Para 1.o	Action 8.a	Indicator 3.3.1	WHO UNAIDS SDGs
	Hepatitis incidence, treatment rate, and mortality among people who use drugs. disaggregated by age and gender ²¹	Para 1.o	Action 8.a	Indicator 3.3.4	WHO UNAIDS

¹⁸ ARQ Part II already tracks availability and coverage – in the community and in prison – of the nine interventions promoted by the UNODC, UNAIDS, WHO Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users – including needle and syringe programmes, ART, hepatitis treatment, etc., but data is not disaggregated by age or gender

²¹ Same as for HIV

¹⁹ While ARQ Part III questions 45-47 and 55 are related to overdoses, the questionnaire currently does not track the distribution of naloxone

²⁰ Questions on HIV are included in ARQ Part III, questions 38-44. This new wording is an attempt at improving data collection and aligning it with the SDGs

					SDGs
	Tuberculosis incidence, prevalence, and death rates among people	Para 1.o	Action 8.a	Indicator 3.3.2	WHO
	who use drugs, disaggregated by age, gender ²²				UNAIDS
					SDGs
PART III: Ensuring	the availability of and access to controlled substances exclusively for	[,] medical and scie	entific purposes, while	preventing their dive	rsion ²³
Target 3: Achieve	a measurable improvement in availability of, and access to, controlle	d substances for	medical and scientific	purposes	
Process indicator	Legislation, regulations or administrative measures	Para 2		Target 3.8	INCB
	adopted/reviewed during the reporting year to improve access to	Para 2.a			
	controlled substances for medical and scientific purposes (e.g.				
	substances available, easier requirements to prescribe;				
	requirements for patients to obtain prior permission or register to				
	be eligible, for physicians to receive special licences, for				
	pharmacies to obtain prior licences to dispense medicines, etc.)				
	Coverage of training for healthcare professionals on palliative care	Para 2.e	Action 5		INCB
	and the treatment of moderate to severe or chronic pain with				SDGs
	controlled medicines				
Outcome indicator	A range of opioids are available and affordable for people with	Para 2.d			INCB
	severe pain	Para 2.g			
	% of people suffering from moderate to severe or chronic pain	Para 2			INCB
	receiving controlled medicines (disaggregated by age and gender)				SDGs
	% of people dependent on opioids receiving substitution therapy	Para 2.a		Target 3.5	
	with methadone, buprenorphine or morphine (disaggregated by	Para 1.k			
	age and gender)	Para 1.o			
	Number of pharmaceutical establishments that can dispense	Para 2.a			INCB
	opioids for pain management per 100,000 inhabitants	Para 2.d			
	% of medical and nursing schools providing palliative care and pain	Para 2.e	Action 5		INCB
	management training in their curriculum				

²² Same as for HIV ²³ So far, the ARQ does not include any section for member states to report back on progress made in accessing internationally controlled substances for medical and scientific purposes

judicial cooperatio					
	a measurable reduction in drug-related crime	1			
Process indicator	Legislation, regulations or administrative measures adopted/reviewed during the reporting year to improve socioeconomic conditions in marginalised communities and prevent involvement in drug-related crime	Para 3.b	Action 35.b	Target 1.1	
	Legislation, regulations or administrative measures adopted/reviewed during the reporting year to improve criminal intelligence, judicial cooperation and border management strategies at national, regional and international level	Para 3.f Para 3.g	Action 11, 18		
Outcome indicator	Extent of high impact intelligence led and targeted activities, of joint operations, joint investigation teams and cross border cooperation initiatives focusing on criminal organisations engaged in illicit drug activity	Para 3.f	Action 11		CCPCJ
	Number of victims of intentional homicide per 100,000 population, by sex and age	Para 3.a		Target 16.1 Indicator 16.1.1	World Bank SDGs
	Proportion of population subjected to physical, psychological or sexual violence in the previous 12 months	Para 3.a			World Bank SDGs
Target 5: Achieve a	a measurable reduction in organized crime, including money-launder	ing, corruption a	nd other criminal activi	ties	
Process indicator	Number of countries having ratified the United Nations Convention against Transnational Organized Crime and the United Nations Convention against Corruption	Para 3.n		Target 16.4	
Outcome indicator	Increased number of financial investigations and confiscations in relation to the proceeds of drug-related organised crime	Para 3.q Para 3.r	Action 18		
	Perception of public sector corruption	Para 3.a		Target 16.5	World Bank

²⁴ Much of Part IV of the ARQ focuses on assessing the scale of the illicit cultivation, production, manufacture and trafficking in internationally controlled substances. Although this may be considered as an important indicator of success, even more important is the impact that drug control strategies can have on addressing violence, corruption and organised crime. It is in this light that we propose the following indicators here

	human rights-based approach in the design and implementation of c		es and programmes air	ning to contribute to	the protectio
of human rights o Process indicator	f youth, women, children, vulnerable members of society, and comn Legislation, regulation or measure passed/reviewed to ensure a	Para 4.n		Target 5.c	ССРСЈ
	gender-sensitive approach to drug policies and programmes, including in the implementation of the Bangkok Rules			Indicator 5.1.1	CSW
	Legislation, regulation or measure passed/reviewed to ensure the involvement of women in all stages of the development, implementation, monitoring and evaluation of drug policies and programmes	Para 4.g		Target 16.7	UN Women
Outcome indicator	Extent of increase in the number of youth- and gender-specific drug dependence and rehabilitation programmes	Para 4.b	Action 7.b		WHO UNAIDS
	Reported cases of gender-based discrimination in accessing health-care, including those directly associated with stigma	Para 4.b	Action 7.d Action 16.a	Target 5.1 Target 10.3 Target 16.A Indicator 10.3.1	UN Women OHCHR ²⁶
	Percentage of referred cases of sexual and gender-based violence against women and children that are investigated and sentenced for a drug offence	Para 4.d	Action 51.h	Target 5.2 Target 16.1 Indicator 11.7.2 Indicator 16.1.3	UN Women OHCHR CSW
Target 7: Achieve criminal justice pr	more proportionate policies and responses for drug offences; and en oceedings	nsure the protect	ion of legal guarantees	and safeguards perta	ining to
Process indicator	Legislation, regulation or measure passed/reviewed to ensure more proportionate penalties for drug offences	Para 4.I		Target 16.3	CCPCJ
	Legislation, regulation or measure passed to provide alternatives to coercion or punishment (type of alternative, for which type of offences) for drug offenders	Para 4.j	Action 22		CCPCJ
	Number of drug offenders who benefited from an alternative to incarceration (disaggregated by age and gender)	Para 4.j	Action 22		CCPCJ

²⁵ Only gender-specific indicators were included here. However, we have identified elsewhere in this Matrix indicators for which data should be disaggregated by age and gender. We also call for gender-disaggregated data for the current ARQ Part II, questions 9, 11, 15; and in Part II questions 12, 18-22, 25-27, 30-33, 48-51 and 54-60

²⁶ The OHCHR has a Working Group focusing on the prevention of discriminations against women in practice and the law. The data collected by the Working Group constitutes a useful source of information for UNODC

	Legislation, regulation or measure passed to eliminate arbitrary arrest and detention against drug offenders	Para 4.o	Action 37.f		OHCHR
	Legislation, regulation or measure passed to eliminate acts of torture and other inhuman, degrading treatment or punishment, including corporal punishment, against drug offenders	Para 4.c Para 4.o	Action 51.h	Target 16.2 Indicator 11.7.2	OHCHR
	Legislation, regulation or measure passed to eliminate impunity	Para 4.o	Action 37.f	Target 16.3	OHCHR
	Training to law enforcement officials on the health and human rights aspects of drug control		Action 50	Target 16.A	OHCHR
Outcome indicator	% of drug offenders incarcerated, compared to the rest of the prison population (disaggregated by age, gender, and type of offence: drug use & simple possession, low-level, mid-level, high- level trafficking or production, manufacture, cultivation)	Para 4.j Para 4.l	Action 22		ССРСЈ
	Number of drug offenders incarcerated (disaggregated by age and	Para 4.j	Action 22		CCPCJ
	gender)	Para 4.I			Civil society
	Proportion of drug offenders held in pre-trial detention	Para 4.j	Action 22	Indicator 16.3.2	CCPCJ
	(disaggregated by age and gender)				Civil society
	Number of drug offenders condemned to the death penalty	Para 4.I	Action 37.f		OHCHR
	(disaggregated by age and gender)				Civil society
	Reported cases of extrajudicial killings of (suspected) drug	Para 4.o	Action 37.f	Target 16.1	OHCHR
	offenders (disaggregated by age and gender)		Action 51.h	Indicator 16.1.1	Civil society
	Reported cases of arbitrary detention during the reporting period (disaggregated by age and gender)	Para 4.o	Action 37.f	Target 16.3	OHCHR Civil society
	Incidence and prevalence of physical and psychological abuse (including sexual violence), including by law enforcement officials, against (suspected) drug offenders (disaggregated by age and gender)	Para 4.o	Action 51.h	Target 16.1 Indicator 11.7.2 Indicator 16.1.3	OHCHR UN Women CSW Civil society
	% of law enforcement officials formally investigated for physical and psychological violence against (suspected) drug offenders, including arbitrary arrest and detention – of which, proportion of formal investigations resulting in disciplinary action or prosecution	Para 4.o	Action 37.f	Target 16.3	OHCHR Civil society
	Number of people who use drugs held in compulsory drug	Para 1.j	Action 51.h		OHCHR
	detention centres (disaggregated by age and gender)	Para 4.o			Civil society

	Other cases of torture or cruel, inhuman or degrading treatment	Para 4.c	Action 51.h	Target 16.1	OHCHR
	or punishment perpetrated by an agent of the state or any person	Para 4.o		Indicator 16.1.3	Civil society
	acting under its authority or with its complicity, against				
	(suspected) drug offenders (disaggregated by age and gender)				
	Proportion of victims of torture or cruel, inhuman or degrading	Para 4.c	Action 51.h	Target 16.3	OHCHR
	treatment or punishment accused of drug offences who have	Para 4.o		Indicator 16.1.3	Civil society
	received compensation and rehabilitation (disaggregated by age				
	and gender)				
	% of people accused of drug offences who received legal aid	Para 4.o		Target 16.5	OHCHR
	during trial (disaggregated by age and gender)				
ART VI: Cross-cut	ting issues: Evolving reality, trends and existing circumstances, eme	rging and persiste	ent challenges and threa	ats, including new psy	ychoactive
substances					
Target 8: Achieve a	a measurable reduction in the threat and harms posed by new psych	oactive substance	es, amphetamine-type	stimulants, including	
-	e and the diversion of precursors and pre-precursors, including adve			, ,	
rocess indicator	Strengthened cooperation to tackle the rising trend of NPS and		Action 29.b		EMCDDA
	ATS use and dependence, focusing on creating and sharing best				WHO
	prostings in proventing the encoded from level enidemics and				UNAIDS
	practices in preventing the spread from local epidemics and				UNAIDS
	sharing information on the prevention of misuse of medicinal				
	sharing information on the prevention of misuse of medicinal	Para 5.d	Action 29.b		
	sharing information on the prevention of misuse of medicinal products for methamphetamine production	Para 5.d	Action 29.b		Civil society
	sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the	Para 5.d	Action 29.b		Civil society
Dutcome indicator	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and 	Para 5.d Para 5.d	Action 29.b	Target 3.5	Civil society
Dutcome indicator	sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants			Target 3.5	Civil society WHO
Dutcome indicator	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based 			Target 3.5 Target 3.3	Civil society WHO WHO
Dutcome indicator	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) 	Para 5.d	Action 29.b		Civil society WHO WHO UNAIDS
Dutcome indicator	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) % of people using NPS and ATS suffering from health harms 	Para 5.d	Action 29.b		Civil society WHO WHO UNAIDS WHO
	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) % of people using NPS and ATS suffering from health harms (including HIV, hepatitis C, tuberculosis, overdoses and others) 	Para 5.d Para 5.d	Action 29.b Action 29.b	Target 3.3	Civil society WHO WHO UNAIDS WHO UNAIDS
Farget 9: Improve	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) % of people using NPS and ATS suffering from health harms (including HIV, hepatitis C, tuberculosis, overdoses and others) (disaggregated by age and gender) 	Para 5.d Para 5.d	Action 29.b Action 29.b	Target 3.3	Civil society WHO WHO UNAIDS WHO UNAIDS
Farget 9: Improve rends and emergi	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) % of people using NPS and ATS suffering from health harms (including HIV, hepatitis C, tuberculosis, overdoses and others) (disaggregated by age and gender) research, data collection, analysis, technical assistance and capacity 	Para 5.d Para 5.d	Action 29.b Action 29.b	Target 3.3	Civil society WHO WHO UNAIDS WHO UNAIDS
Farget 9: Improve	 sharing information on the prevention of misuse of medicinal products for methamphetamine production Availability of innovative, accessible interventions to address the adverse health consequences of new psychoactive substances and amphetamine-type stimulants % of people dependent on NPS and ATS accessing evidence-based treatment (disaggregated by age and gender) % of people using NPS and ATS suffering from health harms (including HIV, hepatitis C, tuberculosis, overdoses and others) (disaggregated by age and gender) research, data collection, analysis, technical assistance and capacity ng and persistent challenges and threats 	Para 5.d Para 5.d building to tackle	Action 29.b Action 29.b	Target 3.3	Civil society WHO WHO UNAIDS WHO UNAIDS

	Enhanced data collection, research, analysis and reporting on emerging trends that pose risks to health and safety	Para 5.x	Action 51.c		EMCDDA WHO UNAIDS
PART VII: Strength	ening international cooperation based on the principle of common a	nd shared respon	sibility		
Target 10: Increase	e technical assistance and cooperation through relevant UN agencies	and internationa	l and regional organization	ons to effectively a	ddress the
health, socioecond	pmic, human rights, justice and law enforcement aspects of the world	d drug problem			
Process indicator	Strengthened technical assistance to effectively address the	Para 6.a	Action 41		
	health, socioeconomic, human rights, justice and law-enforcement				
	aspects of the world drug problem				
Outcome indicator	Number of people having benefited from socioeconomic measures	Para 6.a			
	as part of drug control strategies (disaggregated by age, gender)				
Target 11: Improve	e international cooperation, exchange of information and lessons lea	rned between me	ember states, and with al	I relevant United N	lations
entities, in tackling	g the world drug problem				
Process indicator	Formal and informal mechanisms established to enhance North-	Para 6.b	Action 38, 39, 40	Target 16.a	
	South, South-South and triangular cooperation among Member			Target 17.6	
	States				
	Formal and informal mechanisms established to enhance the	Para 6.e	Action 42		
	participation of all relevant UN entities and international financial				
	institutions, within their respective mandates in drug control				
	policies and programmes, including in the achievement of the				
	Sustainable Development Goals				
Outcome indicator	Level of information sharing through effective coordination	Para 6.c	Action 14	Target 16.a	
	mechanisms at national, regional, subregional and international				
	levels				
	Visibility of drug policy issues in official discussions, reports and	Para 6.d	Action 42		HLPF
	high-level documents produced as part of the achievement of the				SDGs
	Sustainable Development Goals				
PART VIII: Alternat	tive development; regional, interregional and international cooperat	ion on developme	ent-oriented balanced dr	ug control policy; a	ddressing
<mark>socioeconomic</mark> issi	ues				
Target 12: Measur	ably improve the socioeconomic condition of communities in areas a	ffected by cultiva	tion, manufacture, produ	uction and traffick	ng in drugs
Process indicator	Proportion of total government spending on essential services			Indicator 1.A.2	UNDP
	(education, health and social protection)				SDGs

Outcome indicator	Percentage of people living above the poverty line in communities	Para 5.v	Action 35.b and c	Indicator 1.1.1	UNDP
	affected by the drug trade (disaggregated by gender) ²⁷	Para 7.b		Target 16.7	HDI
					SDGs
	Percentage of women, men, indigenous peoples, and local	Para 7.j		Target 1.4	UNDP
	communities with secure rights to land, property, and natural			Indicator 1.4.2	HDI
	resources, measured by (i) percentage with documented or			Indicator 5.A.1	SDGs
	recognized evidence of tenure, and (ii) percentage who perceive			Indicator 5.A.2	
	their rights are recognized and protected				
	Percentage of people having access to stable housing in	Para 7.h		Target 11.1	UNDP
	communities affected by the illicit drug trade (disaggregated by	Para 7.j			HDI
	gender)				SDGs
	Percentage of people having access to primary, secondary and	Para 7.h		Target 4.1	UNDP
	higher education in areas affected by the illicit drug trade	Para 7.j		Indicator 4.3.1	HDI
	(disaggregated by gender)			Indicator 8.6.1	SDGs
	Increase/reduction in the number of people displaced from their	Para 7.j		Target 1.4	UNHCR
	land due to crop eradication activities and other drug law			Indicator 1.4.2	
	enforcement efforts			Indicator 5.A.1	
	Increase/reduction in access to licit markets for products derived	Para 7.b		Target 9.3	UNDP
	from local cultivation, production and manufacture				
Target 13: Increase	ed technical and financial cooperation for the implementation of dev	velopment-oriente	d drug policies and viabl	e economic alterna	atives
Process indicator	Mechanism(s) established for the participation of affected	Para 7.b	Action 35	Target 16.7	UNDP
	communities in policy making and implementation of drug control			Indicator 16.7.2	Civil society
	policies				

²⁷ The Gini Coefficient may also be a useful indicator to look at here

Relevant SDG Tar	gets and Indicators mentioned in the Matrix
Target 1.1	By 2030, eradicate extreme poverty for all people everywhere, currently
U	measured as people living on less than \$1.25 a day
Target 1.4	By 2030 ensure that all men and women, particularly the poor and the
U	vulnerable, have equal rights to economic resources, as well as access to basic
	services, ownership, and control over land and other forms of property,
	inheritance, natural resources, appropriate new technology, and financial
	services including microfinance
Target 3.3	By 2030 end the epidemics of AIDS, tuberculosis, malaria, and neglected
J	tropical diseases and combat hepatitis, water-borne diseases, and other
	communicable diseases
Target 3.4	By 2030 reduce by one-third pre-mature mortality from non-communicable
J	diseases (NCDs) through prevention and treatment, and promote mental
	health and wellbeing
Target 3.5	Strengthen prevention and treatment of substance abuse, including narcotic
	drug abuse and harmful use of alcohol
Target 3.8	Achieve universal health coverage (UHC), including financial risk protection,
	access to quality essential health care services, and access to safe, effective,
	quality, and affordable essential medicines and vaccines for all
Target 4.1	By 2030, ensure that all girls and boys complete free, equitable and quality
	primary and secondary education leading to relevant and effective learning
	outcomes
Target 5.1	End all forms of discrimination against all women and girls everywhere
Target 5.2	Eliminate all forms of violence against women and girls in the public and
	private spheres, including trafficking and sexual and other types of exploitation
Target 5.c	Adopt and strengthen sound policies and enforceable legislation for the
	promotion of gender equality and the empowerment of all women and girls at
	all levels
Target 9.3	Increase the access of small-scale industrial and other enterprises, particularly
	in developing countries, to financial services including affordable credit and
	their integration into value chains and markets
Target 11.1	By 2030, ensure access for all to adequate, safe and affordable housing and
	basic services, and upgrade slums
Target 16.1	Significantly reduce all forms of violence and related death rates everywhere
Target 16.2	End abuse, exploitation, trafficking and all forms of violence and torture
	against children
Target 16.3	Promote the rule of law at the national and international levels, and ensure
	equal access to justice for all
Target 16.4	By 2030 significantly reduce illicit financial and arms flows, strengthen recovery
	and return of stolen assets, and combat all forms of organized crime
Target 16.5	Substantially reduce corruption and bribery in all its forms
Target 16.7	Ensure responsive, inclusive, participatory and representative decision-making
	at all levels
Target 16.A	Strengthen relevant national institutions, including through international
	cooperation, for building capacity at all levels, in particular in developing
	countries, to prevent violence and combat terrorism and crime
Target 16.B	Promote and enforce non-discriminatory laws and policies for sustainable
	development

	Droportion of population below the international poverty line, by cay, age
Indicator 1.1.1	Proportion of population below the international poverty line, by sex, age,
Indianton 1.4.2	employment status and geographical location (urban/rural)
Indicator 1.4.2	Proportion of total adult population with secure tenure rights to land, with
	legally recognized documentation and who perceive their rights to land as
Indicator 1.A.2	secure, by sex and by type of tenure
Indicator 1.A.Z	Proportion of total government spending on essential services (education,
Indicator 3.3.1	health and social protection) Number of new HIV infections per 1,000 uninfected population, by sex, age
	and key populations
Indicator 3.3.2	Tuberculosis incidence per 1,000 population
Indicator 3.3.4	Hepatitis B incidence per 100,000 population
Indicator 3.5.1	Coverage of treatment interventions (pharmacological, psychosocial and
Indicator 3.8.1	rehabilitation and aftercare services) for substance use disorders
Indicator 5.8.1	Coverage of essential health services (defined as the average coverage of
	-
Indicator (1 2 1	
Indicator 5 1 1	
Indicator 5 A 1	
Indicator 5 A 2	
Indicator 8.6.1	
Indicator 10.3.1	
Indicator 11.7.2	
Indicator 16.1.1	
Indicator 16.1.3	
Indicator 16.3.2	Unsentenced detainees as a proportion of overall prison population
Indicator 16.7.2	Proportion of population who believe decision-making is inclusive and
Indicator 16.B.1	Proportion of population reporting having personally felt discriminated against
Indicator 4.3.1 Indicator 5.1.1 Indicator 5.A.1 Indicator 5.A.2 Indicator 5.A.2 Indicator 10.3.1 Indicator 10.3.1 Indicator 11.7.2 Indicator 16.1.3 Indicator 16.1.3 Indicator 16.7.2	essential services based on tracer interventions that include reproductive, maternal, newborn and child health, infectious diseases, non-communicable diseases and service capacity and access, among the general and the most disadvantaged population) Participation rate of youth and adults in formal and non-formal education and training in the previous 12 months, by sex Whether or not legal frameworks are in place to promote, enforce and monitu- equality and non-discrimination on the basis of sex (a) Proportion of total agricultural population with ownership or secure rights over agricultural land, by sex; and (b) share of women among owners or rights bearers of agricultural land, by type of tenure Proportion of countries where the legal framework (including customary law) guarantees women's equal rights to land ownership and/or control Proportion of youth (aged 15-24 years) not in education, employment or training Proportion of the population reporting having personally felt discriminated against or harassed within the previous 12 months on the basis of a ground of discrimination prohibited under international human rights law Proportion of persons victim of physical or sexual harassment, by sex, age, disability status and place of occurrence, in the previous 12 months Number of victims of intentional homicide per 100,000 population, by sex and age Proportion of population subjected to physical, psychological or sexual violenc in the previous 12 months Unsentenced detainees as a proportion of overall prison population Proportion of population who believe decision-making is inclusive and responsive, by sex, age, disability and population group

List of acronyms	
ССРСЈ	Commission on Crime Prevention and Criminal Justice
CSW	Commission on the Status of Women
EMCDDA	European Monitoring Centre on Drugs and Drug Addiction
HDI	Human Development Index

HLPF	High Level Political Forum (on the achievement of the SDGs)
INCB	International Narcotics Control Board
OHCHR	Office of the High Commissioner on Human Rights
SDGs	Sustainable Development Goals
UNAIDS	Joint United Nations Programme on HIV and AIDS
UNDP	United Nations Development Programme
UNHCR	United Nations High Commissioner for Refugees
WHO	World Health Organisation